

James Sun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7140862/publications.pdf>

Version: 2024-02-01

39
papers

512
citations

840119

11
h-index

752256

20
g-index

40
all docs

40
docs citations

40
times ranked

816
citing authors

#	ARTICLE	IF	CITATIONS
1	Mapping cutaneous T-cell lymphoma in the state of Florida: A retrospective exploratory spatial analysis of incidence patterns. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 186-188.	0.6	4
2	In-transit metastatic cutaneous melanoma: current management and future directions. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 201-211.	1.7	6
3	Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Locoregional Melanoma After Failure of Immunotherapy: An International Multi-Institutional Experience. <i>Annals of Surgical Oncology</i> , 2022, 29, 791-801.	0.7	18
4	Patterns of Recurrence and Prognosis in Pathologic Stage I and II Merkel Cell Carcinoma: A multi-center, retrospective cohort analysis. <i>Journal of the American Academy of Dermatology</i> , 2022, . .	0.6	0
5	The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases – A multicenter cohort study. <i>European Journal of Cancer</i> , 2022, 169, 210-222.	1.3	12
6	Feasibility of Axillary Lymph Node Localization and Excision Using Radar Reflector Localization. <i>Clinical Breast Cancer</i> , 2021, 21, e189-e193.	1.1	18
7	Is it Wise to Omit Sentinel Node Biopsy in Elderly Patients with Breast Cancer?. <i>Annals of Surgical Oncology</i> , 2021, 28, 320-329.	0.7	17
8	Surgeon Bias in the Management of Positive Sentinel Lymph Nodes. <i>Clinical Breast Cancer</i> , 2021, 21, 74-79.	1.1	4
9	Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched Analysis. <i>Journal of the American College of Surgeons</i> , 2021, 232, 424-431.	0.2	14
10	Adjuvant Radiation Therapy for Clinical Stage III Melanoma in the Modern Therapeutic Era. <i>Annals of Surgical Oncology</i> , 2021, 28, 3512-3521.	0.7	8
11	Impact of Axillary Dissection Among Patients With Sentinel Node–Positive Breast Cancer Undergoing Mastectomy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 40-47.	2.3	13
12	Response to Letter to the Editor: “Omitting Sentinel Lymph Node Biopsy in Elderly Patients: A Lost Opportunity?” by Todd Tuttle et al.. <i>Annals of Surgical Oncology</i> , 2021, 28, 5444-5445.	0.7	0
13	Predictors of False Negative Sentinel Lymph Node Biopsy in Clinically Localized Merkel Cell Carcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 6995-7003.	0.7	8
14	Real-world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia. <i>Cancer Medicine</i> , 2021, 10, 7665-7672.	1.3	9
15	The combination of encorafenib and binimetinib for the treatment of patients with BRAF-mutated advanced, unresectable, or metastatic melanoma: an update. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 19-29.	0.4	3
16	ASO Visual Abstract: Talimogene Laherparepvec (T-VEC) for Treatment of Advanced Locoregional Melanoma after Failure of Immunotherapy: An International Multi-institutional Experience. <i>Annals of Surgical Oncology</i> , 2021, 29, 804.	0.7	3
17	Robotic-Assisted Pelvic Lymphadenectomy for Metastatic Melanoma Results in Durable Oncologic Outcomes. <i>Annals of Surgical Oncology</i> , 2020, 27, 196-202.	0.7	6
18	Development of Malignancy-Risk Gene Signature Assay for Predicting Breast Cancer Risk. <i>Journal of Surgical Research</i> , 2020, 245, 153-162.	0.8	1

#	ARTICLE	IF	CITATIONS
19	Principles of Targeted Therapy for Melanoma. <i>Surgical Clinics of North America</i> , 2020, 100, 175-188.	0.5	40
20	An evaluation of encorafenib for the treatment of melanoma. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 155-161.	0.9	11
21	Perioperative Outcomes of Melanoma Patients Undergoing Surgery After Receiving Immunotherapy or Targeted Therapy. <i>World Journal of Surgery</i> , 2020, 44, 1283-1293.	0.8	8
22	Factors predicting toxicity and response following isolated limb infusion for melanoma: An international multi-centre study. <i>European Journal of Surgical Oncology</i> , 2020, 46, 2140-2146.	0.5	8
23	Oncologic Outcomes After Isolated Limb Infusion for Advanced Melanoma: An International Comparison of the Procedure and Outcomes Between the United States and Australia. <i>Annals of Surgical Oncology</i> , 2020, 27, 5107-5118.	0.7	8
24	Observational study of talimogene laherparepvec use in the anti-PD-1 era for melanoma in the US (COSMUS-2). <i>Melanoma Management</i> , 2020, 7, MMT41.	0.1	3
25	The Devil's in the Details: Discrepancy Between Biopsy Thickness and Final Pathology in Acral Melanoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 5259-5266.	0.7	5
26	Characteristics of Microinvasive Ductal Carcinoma In Situ Versus Noninvasive and Invasive Breast Cancer. <i>Journal of Surgical Research</i> , 2020, 254, 378-383.	0.8	9
27	International Multicenter Experience of Isolated Limb Infusion for In-Transit Melanoma Metastases in Octogenarian and Nonagenarian Patients. <i>Annals of Surgical Oncology</i> , 2020, 27, 1420-1429.	0.7	10
28	Isolated limb infusion: Institutional protocol and implementation. <i>Journal of Surgical Oncology</i> , 2020, 122, 99-105.	0.8	7
29	Over 12 Years Single Institutional Experience Performing Percutaneous Hepatic Perfusion for Unresectable Liver Metastases. <i>Cancer Control</i> , 2020, 27, 107327482098301.	0.7	7
30	Diagnosis and Management of Cutaneous B-Cell Lymphomas. <i>Dermatologic Clinics</i> , 2019, 37, 443-454.	1.0	18
31	Lymphomatoid Papulosis and Other Lymphoma-Like Diseases. <i>Dermatologic Clinics</i> , 2019, 37, 471-482.	1.0	10
32	Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience. <i>Journal of the American College of Surgeons</i> , 2019, 228, 644-649.	0.2	65
33	Long-Term Oncologic Outcomes After Isolated Limb Infusion for Locoregionally Metastatic Melanoma: An International Multicenter Analysis. <i>Annals of Surgical Oncology</i> , 2019, 26, 2486-2494.	0.7	35
34	Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 381-392.	1.0	62
35	Management of intussusception in patients with melanoma. <i>Journal of Surgical Oncology</i> , 2019, 119, 897-902.	0.8	5
36	The emergence of neoadjuvant therapy in advanced melanoma. <i>Melanoma Management</i> , 2019, 6, MMT27.	0.1	12

#	ARTICLE	IF	CITATIONS
37	Encorafenib/binimetinib for the treatment of BRAF-mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 9081-9089.	1.0	41
38	Pyomyositis in the setting of complicated diverticulitis: case report. <i>International Journal of General Medicine</i> , 2017, Volume 11, 11-14.	0.8	1
39	Advances in the management of genitourinary melanomas. <i>AME Medical Journal</i> , 0, 4, 41-41.	0.4	3